Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya, Turkey.
Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya, Turkey.
Transplant Proc. 2023 Jun;55(5):1176-1181. doi: 10.1016/j.transproceed.2023.01.024. Epub 2023 Feb 27.
COVID-19 has led to an unprecedented global health crisis. This situation caused an immediate reduction in solid organ transplantation activity. This study aimed to present the follow-up results of patients with chronic liver disease who underwent liver transplantation (LT) after a history of COVID-19 infection.
Sociodemographic characteristics and clinicopathological data of 474 patients who underwent LT at Inonu University Liver Transplant Institute between March 11, 2020 and March 17, 2022 were prospectively recorded and analyzed retrospectively. Among these, the data of 35 patients with chronic liver disease who were found to be exposed to COVID-19 infection in the pre-LT period were analyzed for this study.
The median body mass index, Child score, and Model for end-stage liver disease/ Pediatric end-stage liver disease scores of the 35 patients were calculated as 25.1 kg/m (IQR: 7.4), 9 points (IQR: 4), and 16 points (IQR: 10), respectively. Graft rejection occurred in 4 patients at a median of 25 days post-transplant. Five patients underwent retransplantation at a median of 25 days post-transplant. The most common cause of retransplantation is early hepatic artery thrombosis. There were 5 deaths during postoperative follow-up. Mortality developed in 5 (14.3%) patients exposed to COVID-19 infection in the pretransplant period, whereas mortality occurred in 56 (12.8%) patients not exposed to COVID-19 infection. There was no statistically significant difference in mortality between the groups (P = .79).
The results of this study showed that exposure to COVID-19 before LT does not affect post-transplant patients and graft survival.
COVID-19 引发了前所未有的全球卫生危机。这种情况导致实体器官移植活动立即减少。本研究旨在介绍 COVID-19 感染史后接受肝移植 (LT) 的慢性肝病患者的随访结果。
前瞻性记录并回顾性分析了 2020 年 3 月 11 日至 2022 年 3 月 17 日在因努大学肝移植研究所接受 LT 的 474 例患者的社会人口统计学特征和临床病理数据。其中，分析了 35 例慢性肝病患者在 LT 前暴露于 COVID-19 感染的数据。
35 例患者的中位体重指数、Child 评分和终末期肝病模型/儿科终末期肝病评分分别为 25.1kg/m²（IQR：7.4）、9 分（IQR：4）和 16 分（IQR：10）。移植后中位 25 天发生 4 例移植物排斥反应。5 例患者在移植后中位 25 天再次接受移植。再移植最常见的原因是早期肝动脉血栓形成。术后随访期间有 5 例死亡。在移植前暴露于 COVID-19 的 5 例（14.3%）患者发生死亡，而未暴露于 COVID-19 的 56 例（12.8%）患者发生死亡。两组死亡率无统计学差异（P=0.79）。
本研究结果表明，LT 前暴露于 COVID-19 不会影响移植后患者和移植物的存活率。
